Amgen Settles On Bevacizumab And Trastuzumab
Genentech Had Failed To Enjoin Sales Of Biosimilars In US
Executive Summary
Amgen has filed to settle on undisclosed terms patent-infringement litigation involving both its Kanjinti and Mvasi biosimilars, having previously seen originator Genentech fail multiple times to block commercial sales of the products that were launched ‘at risk’.
You may also be interested in...
Amgen Takes Almost 40% Of US Bevacizumab Market
Amgen’s biosimilar revenues were more than $350m in the second quarter of this year, as the company benefitted from the ‘innovator product’ commercialization model across its increasingly broad portfolio of biosimilars.
Updated: Multiple Biosimilars To Avastin Have Launched In EU
Roche’s biggest seller, Avastin, has fallen to biosimilar competition in Europe, with at least one company confirming launch to Generics Bulletin.
Amgen’s Mvasi Biosimilar Survives Restraining Order Bid Again
Amgen has an open road for its Mvasi bevacizumab biosimilar after Genentech’s appeal to enjoin sales, over a notice of commercial marketing technicality, was denied. The US firm continues to weigh up patent-infringement proceedings in separate actions.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: